The outcomes of continuous ambulatory and automated peritoneal dialysis are similar  by Mehrotra, Rajnish et al.
see commentary on page 12
The outcomes of continuous ambulatory and
automated peritoneal dialysis are similar
Rajnish Mehrotra1,2, Yi-Wen Chiu1,3, Kamyar Kalantar-Zadeh1,2 and Edward Vonesh4
1Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California, USA; 2David Geffen School of Medicine at UCLA,
Los Angeles, California, USA; 3Kaohsiung Medical University, Kaohsiung, Taiwan and 4Northwestern University, Chicago, Illinois, USA
Recent reports indicate a decreased mortality risk for patients
on chronic peritoneal dialysis in the United States. We sought
to determine whether a higher use of automated versus
continuous ambulatory peritoneal dialysis was associated
with this improvement. Analyses were carried out using
data from the United States Renal Data System on 66,381
incident patients on chronic peritoneal dialysis in the years
1996–2004 that were adjusted for demographic, clinical,
laboratory and dialysis facility characteristics. Patients were
followed until the time of transfer to other modes of dialysis,
transplant, or death, whichever occurred first, or until their
last follow-up through September 2006. Over time, the risks
were substantially reduced such that the adjusted hazard
ratios for death or technique failure of these patients in the
2002–2004 period were 0.55 (0.53, 0.57) and 0.62 (0.59, 0.64),
respectively, compared with those of incident patients
during the years 1996–1998. The risk improvements for
both modes of dialysis were, however, found to be similar.
Under intent-to-treat, time-dependent, and as-treated
analysis, there was little or no difference in risk for death or
in technique failure. Thus, the improved chronic peritoneal
dialysis outcomes cannot be attributed to a greater use of
automated peritoneal dialysis.
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Since 1996, the proportion of end-stage renal disease patients
undergoing peritoneal dialysis (PD) in the United States has
declined; during the same period, although the 1-year
outcomes of PD patients have improved, those of main-
tenance hemodialysis patients have remained largely un-
changed.1 It is unclear what changes in practice, if any, have
led to improvements in the outcomes of PD patients. Over
this period, there have been important changes, each of
which has the potential to reduce the overall death risk, for
example, decrease in infectious complications in many
centers, increased use of automated PD (APD), and
publication of clinical practice guidelines that may have
improved prescription management.2–4
In the 1980s and the early 1990s, APD was largely used to
optimize volume status in high-average and high transporters.
With the introduction of smaller, portable machines, in many
centers the increased APD use has been fueled by patient and by
physician choice, irrespective of the transport type. Even though
many epidemiological studies have considered continuous
ambulatory PD (CAPD) and APD to be equivalent, several
lines of investigations have questioned that premise. On the one
hand, most studies have shown that APD patients have a lower
peritonitis risk.5 On the other hand, some studies have raised
concern that the daily sodium removal may be lower in APD
patients.4 However, the data are inconsistent whether this lower
sodium removal with APD is associated with worse volume and
blood pressure control.5,6 Furthermore, some single-center
studies have shown a more rapid loss of residual renal function
in APD patients; these findings have not been confirmed in
larger, multi-center studies.6 Finally, a larger number of PD
exchanges during the night-time cycling may be associated with
higher daily protein losses.7 These differences highlight the need
to compare the outcomes of CAPD and APD patients. At least
three studies have compared the probability of transfer to
maintenance hemodialysis (technique failure) and death in
CAPD and APD patients, with inconsistent results.8–10
We undertook this study to compare the risk for death and
technique failure among incident CAPD and APD patients in
the United States using the data from the United States Renal
Data System (USRDS). We also sought to determine whether
the improvement in PD outcomes can be attributed to a
greater use of APD.
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RESULTS
Patient characteristics
Over the 9-year period, starting in 1996, there were 66,381
incident PD patients in the United States. The proportion of
PD patients undergoing APD on day 90 of end-stage renal
disease increased from 30% during 1996–1998 to 40% during
2002–2004 (Table 1). The mean age of APD patients was 0.7
years greater than that of CAPD patients; the former were
also more likely to be male and White. There were small
differences in the prevalence of other coexisting illnesses—
APD patients had a higher prevalence of cardiac arrest or
dysrhythmia, cerebrovascular disease, and malignant neo-
plasm, but had a lower prevalence of chronic obstructive
pulmonary disease and current smoking. Owing to the large
sample size and increased statistical power, there were a
number of statistically significant differences in laboratory
variables reported on Medical Evidence form 2728; however,
none of them were clinically meaningful (Table 1).
There were significant differences in the characteristics of
the facilities where the patients received their care. Summar-
ized in Table 1 are the mean and median numbers of patients
for the facilities where the CAPD and APD patients were
treated in the United States. Among 41,265 incident CAPD
patients with facility-linked census data, the average APD
census count was 15.5 patients per facility (or 41% of the
average PD census count) compared with that of 25.4
patients per facility (or 68% of the average PD census count)
among the 22,574 incident APD patients with facility-linked
census data (Po0.001, Table 1).
Patient survival
Patients were followed up to the time of death, transfer to in-
center maintenance hemodialysis, home hemodialysis, or
‘other’ PD or renal transplantation (Table 2). The median
follow-up period for CAPD and APD patients was 18.3 and
17.6 months, respectively.
On the basis of an intent-to-treat (ITT) analysis, the
adjusted risk for death among incident PD patients during
1999–2001 and 2002–2004 was 14 and 45% lower, respec-
tively, when compared with that among incident patients in
the 1996–1998 period (Table 3 and Figure 1). The adjusted
median life expectancy for incident CAPD and APD patients
in 1996–1998 was 49.6 and 48.4 months, respectively. For
incident CAPD and APD patients during 1999–2001, the
adjusted median life expectancy improved to 57.6 and 57.2
months, respectively. Owing to the shorter period of follow-
up, life expectancies could not be computed for the
2002–2004 cohort period, although the 45% reduction in
adjusted mortality rates for this cohort compared with those
for 1996–1998 suggests a further improvement in median life
expectancy. As shown below, the improvement in outcomes
over time was similar for both CAPD and APD, and there was
no significant interaction between modality and cohort
period (P¼ 0.96).
In an unadjusted ITT analysis, mortality rates of CAPD
and APD were similar over time (APD versus CAPD
unadjusted hazard ratios and corresponding 95% CI: 0–6
months, 0.98 (0.93, 1.04); 6–12 months, 1.13 (1.06, 1.20);
12–18 months, 1.06 (0.99, 1.14); 18–24 months, 1.07 (0.99,
1.16); 24–30 months, 1.01 (0.92, 1.11); 30–36 months, 1.00
(0.90, 1.11); 36þ months, 1.00 (0.93, 1.08)). Similarly, the
frequency of patients according to their modality at day 90
and their outcomes were also similar, although overall
statistical significance was reached owing to the large
numbers of patients (Table 2). Using an ITT non-propor-
tional hazards model, there were no significant differences in
adjusted mortality rates (adjusted for demographic, clinical,
laboratory, and facility characteristics) in patients treated
with CAPD or APD for virtually all the time periods
examined (Table 3, Figure 2a). Similarly, there were little or
no differences in the adjusted mortality rates for any of the
time periods in incident patients treated with CAPD or APD
under a time-dependent as-treated analysis (Figure 2b). The
hazard ratios for the confounding variables under the as-
treated analysis were almost identical to those shown in
Table 3 for the ITT analysis (data not shown). Figure 3 shows
the population-averaged adjusted ITT patient survival curves
for CAPD and APD patients. These survival curves
correspond to the time-dependent hazard ratios shown in
Figure 2a, for APD versus CAPD. Included in Figure 3 is the
time-independent or average adjusted hazard ratio of 1.03
(95% CI: (0.99, 1.06)) obtained under a proportional hazards
model (adjusted for demographic, clinical, laboratory, and
facility characteristics) and indicates a similar risk of death
with APD and CAPD (Figure 3). As indicated in Table 3,
there was a trend toward improved survival among
centers with larger numbers of period-prevalent hemodialysis
or PD patients, although the overall P-value comparing the
five hemodialysis center census categories did not reach
significance (P¼ 0.07), nor did the overall P-value for
comparing the four PD center census categories (P¼ 0.23).
Note that the category listed as ‘Facility count¼ 0’ under
hemodialysis center census corresponds to patients from a
PD-only facility.
Technique failure
The adjusted risk for technique failure (transfer to main-
tenance hemodialysis for 460 days, censoring for death)
among incident CPD patients during 1999–2001 and
2002–2004 was 10 and 38% lower, respectively, than that
among incident patients in the 1996–1998 period (Table 4).
The improvement in outcomes over time was similar for both
CAPD and APD, and there was no significant interaction
between modality and cohort period.
On the basis of unadjusted outcomes, a larger proportion
of CAPD patients transferred to maintenance hemodialysis,
compared with APD patients (Table 2). However, under an
ITT non-proportional hazards regression analysis, there were
no significant differences in either the time-dependent or
overall relative risk for technique failure (adjusted for
demographic, clinical, laboratory, and facility characteristics)
between CAPD and APD patients (Table 4, Figures 4 and 5a).
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Table 1 | Select characteristics of patients undergoing CAPD and APD on day 90 of end-stage renal disease
CAPD (n = 42,942) APD (n = 23,439) P-value
Cohort period, n
1996–1998 17,174 7243
1999–2001 13,619 7967
2002–2004 12,149 8229
Age, years 56.4±15.1 57.1±15.6 o0.001
Gender, % male 52.6 55.6 o0.001
Race, %
Whites 72.2 74.5 o0.001
Blacks 20.8 19.6
Asians 4.5 3.2
Others 2.5 2.7
Cause of end-stage renal disease
Diabetes 46.1 45.4 o0.05
Hypertension 21.6 21.9
Glomerulonephritis 14.9 14.6
Others 17.3 18.1
Cardiac arrest or dysrhythmia, % 4.9 5.3 o0.05
Cerebrovascular disease, % 6.4 6.9 o0.01
Congestive heart failure, % 22.2 21.5 NS
Ischemic heart disease or myocardial infarction, % 21.7 22.0 NS
Peripheral vascular disease, % 11.2 11.3 NS
Limited activities of daily living, % 1.3 1.5 o0.05
Chronic obstructive pulmonary disease, % 4.5 4.1 o0.05
Current smokers, % 6.2 5.4 o0.001
Diabetes (primary or secondary), % 47.2 46.5 NS
Malignant neoplasm, % 3.5 3.9 o0.01
Body mass index, kg/m2 26.9±6.5 26.8±6.4 NS
Hemoglobin, g per 100 ml 10.3±1.8 10.3±1.8 o0.001
Serum albumin, g per 100 ml 3.5±0.7 3.5±0.7 NS
Blood urea nitrogen, mg per 100 ml 83.2±29.3 83.8±29.3 o0.01
Serum creatinine, mg per 100 ml 7.5±3.3 7.5±3.3 NS
Estimated glomerular filtration rate, ml/min per 1.73 m2 8.8±4.0 8.9±4.0 o0.001
Center census period-prevalent patient numbers (n = 41,265) (n = 22,574)
All dialysis patients
mean±s.d.a 135.0±73.2 133.5±75.7 o0.001
median (range)b 124 (2, 478) 119 (1, 478) o0.05
Peritoneal dialysis patients
mean±s.d. 38.2±28.0 37.3±30.2 o0.001
median (range) 31 (1, 202) 28 (1, 202) o0.001
CAPD patients
mean±s.d. 22.7±19.7 12.0±14.3 o0.001
median (range) 17 (0, 135) 7 (0, 135) o0.001
APD patients
mean±s.d. 15.5±15.6 25.4±22.7 o0.001
median (range) 11 (0, 121) 18 (0, 128) o0.001
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis.
aValues represent the average facility count among patients with linked facility-level data.
bP-values based on the Wilcoxon rank sum test.
Table 2 | Unadjusted outcomes of patients undergoing CAPD and APD on day 90 of end-stage renal disease
CAPD (n = 42,942) APD (n = 23,439)
Event n % Patients n % Patients Pearson’s v2 P-value
Treated with same PD modality 6929 16.1 4214 18.0 o0.001
Death 14,189 33.0 7626 32.5
Transfer to in-center HD 13,295 31.0 6760 28.8
Transfer to home HD/other PD 1374 3.2 812 3.5
Transplant 7155 16.7 4027 17.2
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis; PD, peritoneal dialysis.
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Table 3 | Summary of overall, ITT, non-proportional hazard regression for mortality in incident chronic PD patients between
1996 and 2004 (CAPD, n = 42,803; APD, n = 23,345)
Variable Reference
Hazard ratio
(95% confidence interval) Overall P-value
Cohort period 1996–1998 o0.0001
1999–2001 0.86 (0.83, 0.88)
2002–2004 0.55 (0.53, 0.57)
Intervalmodality (months) CAPD 0.03
0–6 0.98 (0.92, 1.04)
6–12 1.12 (1.05, 1.20)
12–18 1.05 (0.98, 1.13)
18–24 1.06 (0.97, 1.15)
24–30 1.00 (0.91, 1.10)
30–36 0.97 (0.87, 1.09)
36–161 0.97 (0.90, 1.05)
Age, years 18–44 years o0.0001
45–64 2.07 (1.96, 2.19)
65+ 4.18 (3.96, 4.41)
Male gender Female 0.92 (0.89, 0.95) o0.0001
Race White o0.0001
Asian 0.60 (0.55, 0.65)
Black 0.77 (0.74, 0.80)
Other/unknown 0.81 (0.74, 0.88)
Cause of ESRD Diabetes o0.0001
Hypertension 0.82 (0.78, 0.86)
Glomerulonephritis 0.56 (0.53, 0.60)
Other 0.82 (0.78, 0.87)
Cardiac arrest or dysrhythmia No 1.19 (1.13, 1.25) o0.0001
Cerebrovascular disease No 1.27 (1.22, 1.33) o0.0001
Congestive heart failure No 1.41 (1.36, 1.45) o0.0001
Ischemic heart disease or myocardial infarction No 1.18 (1.14, 1.22) o0.0001
Peripheral vascular disease No 1.16 (1.12, 1.21) o0.0001
Limited activities of daily living No 2.04 (1.87, 2.22) o0.0001
Chronic obstructive pulmonary disease No 1.19 (1.13, 1.26) o0.0001
Current smokers No 1.07 (1.01, 1.14) 0.02
Diabetes (primary or secondary) No 1.08 (1.03, 1.13) 0.0009
Malignant neoplasm No 1.25 (1.17, 1.33) o0.0001
Body mass index quintiles (kg/m2) o21.88 kg/m2 o0.0001
21.88–24.61 0.90 (0.86, 0.94)
24.61–27.43 0.82 (0.79, 0.86)
27.43–31.37 0.86 (0.82, 0.90)
431.37 0.94 (0.89, 0.98)
Data missing 0.93 (0.89, 0.98)
Hemoglobin quintiles (g per 100 ml) o8.9 g per 100 ml o0.0001
8.9–9.9 0.99 (0.95, 1.04)
9.9–10.7 0.90 (0.86, 0.95)
10.7–11.7 0.92 (0.88, 0.97)
411.7 0.89 (0.84, 0.93)
Data missing 0.92 (0.87, 0.97)
Serum albumin quintiles (g per 100 ml) o2.9 g per 100 ml o0.0001
2.9–3.4 0.86 (0.82, 0.90)
3.4–3.7 0.76 (0.72, 0.79)
3.7–4.0 0.67 (0.63, 0.70)
44.0 0.55 (0.52, 0.58)
Data missing 0.78 (0.74, 0.81)
Blood urea nitrogen quintiles (mg per 100 ml) o59 mg per 100 ml o0.0001
59–73 0.97 (0.93, 1.02)
73–87 1.05 (0.99, 1.10)
87–105 1.14 (1.09, 1.20)
4105 1.30 (1.24, 1.36)
Data missing 1.05 (0.99, 1.12)
Table 3 continued on following page
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Under a time-dependent as-treated analysis, there were
significant differences in technique failure rates over time.
Among patients on APD at the time, the technique failure
rate was significantly lower in the early (0–6) and later
(30–36) months, but significantly higher in most of the
intervening period (6–24 months) (Figure 5b). The hazard
ratios for the confounding variables under the as-treated
analysis were almost identical to that with the intention-to-
treat analysis (data not shown). There was a graded,
significant inverse relationship between the number of CPD
patients and technique failure (Table 4).
Table 3 | Continued
Variable Reference
Hazard ratio
(95% confidence interval) Overall P-value
Glomerular filtration rate quintiles (ml/min per 1.73 m2) o5.65 ml/min per 1.73 m2 o0.0001
5.65–7.18 1.11 (1.05, 1.16)
7.18–8.84 1.18 (1.12, 1.24)
8.84–11.41 1.27 (1.21, 1.34)
411.41 1.60 (1.52, 1.68)
Data missing 1.95 (1.77, 2.15)
Type of center For profit 0.89
Not for profit 1.01 (0.98, 1.04)
Unknown 1.05 (0.79, 1.40)
Period prevalent HD patient census (count) 1–35 0.07
36–59 0.97 (0.91, 1.04)
60–90 0.95 (0.89, 1.01)
490 0.93 (0.87, 0.99)
Facility count = 0 0.95 (0.88, 1.02)
Period prevalent PD patient census (count) 1–5 0.23
6–12 0.94 (0.87, 1.01)
13–24 0.93 (0.86, 0.99)
424 0.93 (0.87, 0.99)
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; ESRD, end-stage renal disease; HD, hemodialysis; ITT, intention to treat; PD, peritoneal
dialysis.
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Figure 1 | Adjusted, intent-to-treat, patient survival among
incident chronic peritoneal dialysis patients undergoing
continuous ambulatory peritoneal dialysis or automated
peritoneal dialysis in the United States in two cohort periods.
Compared with 1996–1998 incident PD patients, the hazard ratio
for death for the incident patients in the 1999–2001 cohort was
0.86 (0.83–0.88).
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Figure 2 | Adjusted hazard ratio for death, using non-
proportional hazards, among patients undergoing automated
peritoneal dialysis compared with those undergoing
continuous ambulatory peritoneal dialysis between 1996 and
2004. (a) Intent-to-treat and (b) as-treated analyses. Data are
adjusted for cohort period, demographics, clinical, laboratory, and
baseline facility characteristics.
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DISCUSSION
This study provides several valuable pieces of new informa-
tion about the outcomes of PD patients in the United States.
First, there have been substantial reductions in the adjusted
risk for death and technique failure among incident PD
patients since 1996. Second, the outcomes of CAPD and APD
patients are remarkably similar and the improvement in PD
outcomes cannot be attributed to a greater use of APD.
Third, centers with a higher PD utilization had a significantly
lower risk of technique failure and marginally lower risk of
death.
In this study, we examined the adjusted risk for death in
incident PD patients in three 3-year cohorts, starting in 1996.
The risk for death and technique failure among incident PD
patients in 2002–2004 was 45 and 38%, respectively, lower
than that in 1996–1998. To our knowledge, this study
provides one of the most comprehensive evidence of the
improvement in PD outcomes to date. We have reported
earlier an improvement in the 1-year adjusted risk for death
or transfer to maintenance hemodialysis among incident PD
patients;1 this study extends those findings and shows an
improvement in the long-term outcomes as well. Mujais and
Story8 also reported a small reduction in unadjusted 1-year
mortality among 40,869 PD patients in the United States.
However, the study was limited to patients who used supplies
from Baxter Healthcare, included patients transferred from
maintenance hemodialysis (and thus, included both incident
and prevalent patients), was limited to a 4-year period
(2000–2003), and did not include any multivariate analyses
for change in outcome over time.8
To our knowledge, this is the first study that has
documented a progressive and substantial reduction in
technique failure among incident PD patients in the United
States. An increased technique success implies that fewer PD
patients needed to transfer to maintenance hemodialysis—an
event that is both expensive and often associated with patient
morbidity. It follows, then, that the cost-savings with the use
of PD are likely to have increased over the study period;
however, this remains speculative.
During the period examined, a larger proportion of
patients were treated with APD, and we sought to determine
whether the improvement in PD outcomes was a result of
greater APD use. However, we were unable to show any
significant differences in the risk for either death or technique
failure among CAPD and APD patients. Furthermore, there
was no significant interaction between modality and cohort
period showing that there were similar improvements in
outcomes with both modalities.
With the increasing use of APD in the United States and
elsewhere, and some single-center studies raising concern
about the therapy (lower daily sodium removal, faster loss of
residual renal function), it is critically important to compare
the outcomes of CAPD and APD patients. Two randomized,
controlled trials have been undertaken to date and have
shown similar outcomes with the two modalities.11,12
However, only 139 subjects were enrolled in the two trials
put together; hence, these studies were under-powered to
detect any differences in risk for death or technique failure. In
the last 2 years, three observational studies have compared
the effect of PD modality on patient outcomes—one each
including centers in the United States that use Baxter supplies
(n¼ 40,869), from the Australia New Zealand Registry
(ANZDATA) (n¼ 4128), and a single-center study from
Mexico (n¼ 237).8–10 One of these studies showed lower risk
for death (Mexico), and two of these showed a lower
technique failure (the United States and Mexico). We, on the
other hand, were unable to show any difference in the risk for
either death or technique failure between CAPD and APD
subjects.
There are several strengths of this study that significantly
increase the robustness of our findings. First, we included all
incident patients in the United States over the 9-year period.
This makes it the largest study to date that has looked into
this question (n¼ 66,381). Second, comparisons of CAPD
and APD outcomes are often hampered on how to deal with
patients who transfer between these two modalities. Some
investigators have tried to overcome this limitation by ITT
analysis (Baxter), whereas others have assigned patients to
APD as long as they had been treated with the therapy for at
least one period (ANZDATA).8,9 Furthermore, generally,
studies have assumed that the outcomes are proportional
over time. We believe we have overcome each of the above
limitations in that both ITT and time-dependent as-treated
analyses were performed and non-proportional hazards
models were used to study relative risk for APD patients,
compared with those for CAPD patients, in six 6-month
intervals. Finally, the hazards were estimated after compre-
hensive multivariate adjustment. Whereas the study from
Mexico reported only the results of the univariate analysis,
the Baxter Healthcare study used only limited multivariate
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Figure 3 | Adjusted, intent-to-treat patient survival among
patients undergoing continuous ambulatory peritoneal
dialysis and automated peritoneal dialysis in the United
States between 1996 and 2004. Survival curves are based on the
assumption of non-proportional hazards and are adjusted for
cohort period, demographics, clinical, laboratory, and baseline
facility characteristics. An overall adjusted hazard ratio based on a
proportional hazard model is included. With CAPD patients as the
reference group, the hazard ratio for death for APD patients was
1.03 (0.99, 1.06).
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Table 4 | Summary of overall, intention-to-treat, non-proportional hazard regression for technique survival in incident chronic
peritoneal dialysis patients between 1996 and 2004 (CAPD, n = 42,803; APD, n = 23,345)
Variable Reference
Hazard ratio
(95% confidence interval) Overall P-value
Cohort period 1996–1998 o0.0001
1999–2001 0.90 (0.87, 0.93)
2002–2004 0.62 (0.59, 0.64)
Intervalmodality (months) CAPD 0.11
0–6 0.98 (0.92, 1.04)
6–12 1.05 (0.98, 1.13)
12–18 1.05 (0.97, 1.13)
18–24 1.05 (0.96, 1.15)
24–30 0.99 (0.91, 1.09)
30–36 0.93 (0.83, 1.03)
36–161 0.93 (0.84, 1.02)
Age, years 18–44 years o0.0001
45–64 1.03 (0.99, 1.07)
65+ 1.14 (1.10, 1.19)
Male gender Female 1.05 (1.01, 1.08) 0.004
Race White o0.0001
Asian 0.70 (0.65, 0.76)
Black 1.16 (1.12, 1.20)
Other/unknown 0.97 (0.89, 1.06)
Cause of ESRD Diabetes o0.0001
Hypertension 0.88 (0.83, 0.93)
Glomerulonephritis 0.83 (0.78, 0.88)
Other 0.87 (0.82, 0.92)
Cardiac arrest or dysrhythmia No 0.95 (0.88, 1.02) 0.17
Cerebrovascular disease No 1.12 (1.05, 1.19) 0.0003
Congestive heart failure No 1.01 (0.97, 1.05) 0.58
Ischemic heart disease or myocardial infarction No 0.98 (0.94, 1.02) 0.28
Peripheral vascular disease No 1.03 (0.98, 1.09) 0.19
Limited activities of daily living No 1.12 (0.97, 1.30) 0.13
Chronic obstructive pulmonary disease No 1.04 (0.96, 1.12) 0.39
Current smokers No 1.15 (1.09, 1.22) o0.0001
Diabetes (primary or secondary) No 1.03 (0.98, 1.08) 0.23
Malignant neoplasm No 1.08 (1.00, 1.17) 0.04
Body mass index quintiles (kg/m2) o21.88 kg/m2 o0.0001
21.88–24.61 1.03 (0.98, 1.08)
24.61–27.43 1.06 (1.01, 1.11)
27.43–31.37 1.15 (1.10, 1.21)
431.37 1.37 (1.30, 1.44)
Data missing 1.02 (0.96, 1.08)
Hemoglobin quintiles (g per 100 ml) o8.9 g per 100 ml o0.0001
8.9–9.9 0.97 (0.93, 1.02)
9.9–10.7 0.94 (0.89, 0.98)
10.7–11.7 0.90 (0.86, 0.95)
411.7 0.88 (0.84, 0.93)
Data missing 0.95 (0.90, 1.00)
Serum albumin quintiles (g per 100 ml) o2.9 g per 100 ml o0.0001
2.9–3.4 0.89 (0.85, 0.94)
3.4–3.7 0.86 (0.81, 0.91)
3.7–4.0 0.81 (0.76, 0.85)
44.0 0.77 (0.73, 0.81)
Data missing 0.88 (0.83, 0.92)
Blood urea nitrogen quintiles (mg per 100 ml) o59 mg per 100 ml 0.39
59–73 0.99 (0.94, 1.04)
73–87 0.96 (0.91, 1.00)
87–105 0.98 (0.93, 1.03)
4105 0.96 (0.91, 1.01)
Data missing 0.95 (0.89, 1.01)
Table 4 continued on following page
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adjustment (age, gender, diabetes, patient type, and center
census).8,10 In addition to adjusting the data for a large
number of demographic, clinical, and laboratory variables,
facility characteristics were included in the multivariate
models.
Over the last few years, studies from Canada, the
Netherlands, and the United States have shown the
importance of cumulative physician experience, and center
Table 4 | Continued
Variable Reference
Hazard ratio
(95% confidence interval) Overall P-value
Glomerular filtration rate quintiles (ml/min per 1.73 m2) o5.65 ml/min per 1.73 m2 0.01
5.65–7.18 1.01 (0.97, 1.06)
7.18–8.84 1.04 (0.99, 1.09)
8.84–11.41 1.06 (1.01, 1.11)
411.41 1.07 (1.01, 1.13)
Data missing 0.88 (0.78, 1.01)
Type of center For profit 0.10
Not for profit 0.97 (0.94, 1.00)
Unknown 0.81 (0.60, 1.10)
Period prevalent HD patient census (count) 1–35 o0.0001
36–59 1.04 (0.96, 1.12)
60–90 1.04 (0.96, 1.11)
490 1.10 (1.02, 1.17
Facility count = 0 0.84 (0.77, 0.92)
Period prevalent PD patient census (count) 1–5 o0.0001
6–12 0.91 (0.84, 0.98)
13–24 0.80 (0.75, 0.86)
424 0.72 (0.67, 0.77)
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; ESRD, end-stage renal disease; HD, hemodialysis; ITT, intention to treat; PD, peritoneal
dialysis.
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Figure 4 | Adjusted, intent-to-treat technique survival among
patients undergoing continuous ambulatory peritoneal
dialysis and automated peritoneal dialysis in the United
States between 1996 and 2004. Technique survival curves are
based on the assumption of non-proportional hazards and are
adjusted for demographics, clinical, laboratory, and baseline
facility characteristics. An overall adjusted hazard ratio based on a
proportional hazard model is included. With CAPD patients as the
reference group, the hazard ratio for technique failure for APD
patients was 1.00 (0.97, 1.03).
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Figure 5 | Adjusted hazard ratio for technique survival, using
non-proportional hazards, among patients undergoing
automated peritoneal dialysis compared with those
undergoing continuous ambulatory peritoneal dialysis
between 1996 and 2004. (a) Intent-to-treat and (b) as-treated
analysis. Data are adjusted for cohort period, demographics,
clinical, laboratory, and baseline facility characteristics.
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census on outcomes of PD patients.8,13,14 This study further
expands our knowledge of the center census effect on
outcomes. First, the proportion of PD patients in a dialysis
unit in the United States that are treated with APD is, to a
large extent, determined by the dialysis facility where they are
treated. Indeed, among 41,265 incident CAPD patients with
facility-linked census data, the average APD census count
constituted 41% of the average PD census count, compared
with 68% for units where the 22,574 incident APD patients
with facility-linked census data were treated (Po0.001,
Table 1). Thus, the dialysis facility is an important
determinant of selection of the PD modality. Second, we
were able to identify a trend toward lower mortality in larger
centers, although, when compared jointly across all center
size categories, this trend did not reach statistical significance.
Third, we identified a significant decreasing trend in
technique failure with increasing numbers of PD patients.
In addition to larger cumulative experience, dialysis facilities
with a larger PD patient census are likely to have resolved
‘system’ and infrastructure issues (such as availability of
nurses on call, procedures for catheter placement and care,
protocols to reduce infectious risk), which serve to reduce the
risk for transfer to maintenance hemodialysis. Adjusting data
for facility characteristics further strengthens the robustness
of our conclusion that CAPD and APD patients have similar
outcomes.
Despite its strength, this study is not without limitations.
First, there may be some risk for ascertainment bias vis-a`-vis
PD modality. We used the definition traditionally used to
determine the initial PD modality (implying the modality
with which the patient was being treated on day 90 of end-
stage renal disease). Using this definition, 40% of incident
patients were initially treated with APD between 2002 and
2004. In contrast, almost 60% of patients using Baxter
Healthcare supplies were reported to being treated with
APD.8 However, the interval between the date of onset of
ESRD and the ascertainment of PD modality was not
reported. Moreover, the USRDS data used herein is likely
to be more reliable with regard to the date of onset of ESRD,
treatment with non-PD modalities, and, thus, ascertainment
of the initial PD modality. Second, there may be selection
bias such that high transporters may more likely be assigned
to APD than to CAPD, and data on peritoneal transport type
are not available in the USRDS. High transporters have been
reported earlier to have a higher risk for death and technique
failure.15 This, in turn, may have biased the data toward the
null hypothesis. However, there are several reasons why this is
unlikely to be the case. The use of APD obviates the higher
risk for death or technique failure seen in high transporters
treated with CAPD.15 Consistent with these findings, despite
adjustment for peritoneal transport rate in the ANZDATA
analyses, there was no demonstrable difference in the risk for
death or technique failure in CAPD and APD patients.9 As
discussed earlier, dialysis facility was a strong determinant of
the proportion of patients treated with APD. The difference
in APD use by dialysis facilities is more likely to be a result of
provider preference rather than a systematic difference in
patients’ peritoneal transport type. Thus, it appears unlikely
that selection bias may have affected our results. Third, APD
is a heterogeneous therapy and the prescription may vary by
the duration and the number of exchanges of nighttime
cycling and the number of daytime exchanges. This
information was unavailable and we cannot be certain
whether varying the APD prescription has an effect on
patient outcomes. Finally, we cannot exclude residual
confounding, as the reporting of coexisting illnesses on the
Medical Evidence form 2728 is often incomplete.16 However,
recent studies suggest that a more comprehensive adjustment
for coexisting illnesses when performing survival studies in
dialysis patients does not appear to alter the hazard ratios.17
Moreover, the error is likely to be random and probably
equally likely for CAPD and APD patients. These considera-
tions suggest that despite the limitation of data on coexisting
diseases, our findings of similar outcomes with CAPD and
APD are likely to be robust.
In conclusion, in this study, we show a continued and
substantial reduction in the risk of death and technique
failure for PD patients. Patients treated with CAPD and APD
have similar outcomes, which have improved similarly over
the same time period. Thus, improvement of the PD
outcomes over the studied period cannot be attributed to a
greater use of APD. Reduced infectious risk, or more selective
assignment of patients to the therapy over time, or better
prescription management may account for the improved PD
outcomes.
MATERIALS AND METHODS
Data source
The study protocol was reviewed and approved as exempt by the
Institutional Review Board at Los Angeles Biomedical Research
Center. The data for all incident patients over a 9-year period (1996
through 2004) were obtained from the Patient and MEDEVID files
of the USRDS. The data were linked to the RXHIST60 file to assign
treatment modality and to the Facility File to ascertain selected
characteristics of the dialysis unit.
Definitions
As is the convention, the dialysis modality 90 days after the first
service date and continuous treatment for at least 60 days (‘60-d
rule’) was considered to be the initial modality.18 Information on
the presence/absence of various coexisting illnesses and the initial
laboratory results was obtained from the Medical Evidence Form
2728. The unit affiliation was defined as the dialysis facility where
the patient was being treated on day 90 of end-stage renal disease.
Each patient’s data was linked with the facility data from the same
year as the one in which the patient was deemed to be incident. The
patient census in the facility file refers to the point-prevalent count
of patients undergoing treatment with each modality on 31
December of the survey year. However, for the purposes of this
analysis, we enumerated a period-prevalent count obtained by
adding to the point-prevalent facility count those incident patients
who started the year in the facility but whose follow-up ended before
31 December of the given survey year (as determined by the patient-
level data). For this analysis, only patients in whom the modality on
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day 90 was either CAPD or APD were included; patients undergoing
treatment with ‘other’ PD were excluded. Patients from facilities
with missing census data or whose census total was 0 for a given
survey year were excluded from all analyses that adjust for facility-
level characteristics (2542 of the 66,381 incident CPD patients or
3.8%).
Statistical analyses
Baseline characteristics of CAPD and APD patients were compared
using Pearson w2 tests for categorical variables and the Student t-test
for continuous variables. Patients were followed till the time of
transfer to maintenance hemodialysis, home hemodialysis, ‘other’
PD, transplant, or death, whichever happened first, or till the time of
last follow-up (30 September 2006). Proportional and non-
proportional hazards models using a piecewise exponential survival
model (or the interval Poisson regression model) were used to
compare case-mix adjusted mortality and technique failure rates
between CAPD and APD at successive 6-month intervals through
the first 36 months.19–21 Average or time-independent hazard ratios
of death and technique failure for APD compared with CAPD
patients were estimated using a proportional hazards model,
whereas time-dependent relative risks and adjusted patient survival
curves were estimated with a non-proportional hazards model.
Hazard ratios and corresponding 95% CIs were adjusted for case-
mix differences in cohorts, age, gender, race, cause of end-stage renal
disease, individual comorbidities, baseline body mass index,
estimated glomerular filtration rate, baseline laboratory values
(hemoglobin, blood urea nitrogen, and albumin), type of dialysis
facility (for-profit, non-profit, other), and dialysis facility census
(period-prevalent numbers of hemodialysis and PD patients). To
avoid imputing missing values with respect to patient-level data and
making unnecessary parametric assumptions (e.g., assuming age has
a linear effect on the log-risk of death), age, body mass index,
estimated glomerular filtration rate, and all three laboratory
variables were analyzed as discrete categorical variables.22,23 Missing
laboratory values were categorized as not available within the
various analyses, a strategy that has been used successfully in earlier
studies to avoid excluding patients with missing values (http://
www.nature.com/ki/journal/v66/n6/full/4494902a.html).22,23 All
analyses were carried out using the SAS statistical software package
(version 9.2, SAS Inc., Cary, NC, USA); in particular, the GENMOD
procedure was used to fit the data using a piecewise exponential
survival model (both proportional hazards and non-proportional
hazards) as implemented by the interval Poisson regression.
Additional analyses based on the Cox proportional hazards model
were also run, but, as has been shown earlier, the results were nearly
identical with those obtained under the piecewise exponential
survival model (data not shown).19 The piecewise exponential
survival model was chosen for its flexibility in providing adjusted
population-averaged survival curve estimates.
The primary analysis was carried out using an ITT approach in
which death or technique failure was assigned to a patient’s initial
treatment modality regardless of a change in therapy during the
course of follow-up. A time-dependent as-treated analysis was also
performed, in which the event of interest (i.e., death or technique
failure) was assigned to the modality the patient was on at the time
of the event or in those cases where patients switched from CAPD to
APD or vice versa, within 60 days after the switch in therapy. In this
latter case, any event (i.e., death or transfer to maintenance
hemodialysis) that occurred within 60 days after a therapy change
was attributed to the prior treatment modality. To confirm results
comparing APD and CAPD patient and technique survival, as well
as confirm trends in patient outcomes over the three cohort periods
for all 66,381 patients, a second set of analyses was performed
excluding adjustments for facility-level characteristics. The results
were nearly identical with those reported here (data not shown).
Model goodness of fit was assessed by both a likelihood ratio test
and quasi-likelihood ratio test, in which higher order ITT models
containing select interactions with treatment modality (i.e., cohort
by modality, age by modality, and diabetes by modality) were
compared with the ITT models reported on in this manuscript.
These higher order models were compared against the models
without interactions so as to rule out earlier identified interaction
effects that are known to be present in mortality comparisons
between PD and hemodialysis.24 For both mortality and technique
failure, the likelihood ratio and quasi-likelihood ratio tests were not
significant (P40.32 in all cases), indicating the models used in this
manuscript provide a reasonable fit to the observed rate of events.
Finally, adjusted population-averaged survival curves were com-
puted using the direct adjusted survival curve approach described by
Zhang et al.24 From these, median life expectancies were computed
using life table methodology.25
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